Drug intelligence / Profile preview

tiapamil

Development stage: Discontinued
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

**Tiapamil** is an experimental calcium channel blocker structurally related to verapamil, developed as a potential antianginal and antiarrhythmic agent. It selectively inhibits slow calcium channels, demonstrating efficacy in treating ventricular arrhythmias, angina pectoris, acute myocardial infarction, and hypertension with reduced hypotensive, negative inotropic, and negative chronotropic side effects compared to verapamil. Never marketed, it has been studied for hemodynamic benefits in coronary artery disease and as an antihypertensive alternative to diuretics, with additional exploration in central nervous system diseases.

Other names: dimeditiapramine

Targets

LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on tiapamil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tiapamil.

Explore the full profile